BASSAM AWWA: Open Payments
NPI 1881774354 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,200 in 190 payments from 18 companies in 2025. Trend: 2023 $14,815 · 2024 $3,381 · 2025 $4,200
Food & beverage: $4,200
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 25 | $598 |
| Janssen Pharmaceuticals, Inc | 12 | $529 |
| Axsome Therapeutics, Inc. | 27 | $430 |
| Vanda Pharmaceuticals Inc. | 12 | $384 |
| ABBVIE INC. | 25 | $341 |
| Supernus Pharmaceuticals, Inc. | 19 | $304 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $219 |
| Teva Pharmaceuticals USA, Inc. | 7 | $213 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $189 |
| Corium, LLC | 9 | $177 |
Products named: COBENFY, SPRAVATO, FANAPT, VRAYLAR, Qelbree, Sunosi, CAPLYTA, REXULTI.
Industry payments across CT — which companies pay providers there.
